Selegiline remarkably improved stage 5 treatment-resistant major depressive disorder: a case report

We report a case in which selegiline, an irreversible monoamine oxidase B (MAO-B) inhibitor, greatly improved depressive symptoms in an adult with stage 5 treatment-resistant major depressive disorder. Four antidepressants and four augmentation therapies had previously been ineffective or intolerabl...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Kitaichi, Yuji, Inoue, Takeshi, Mitsui, Nobuyuki, Nakagawa, Shin, Kameyama, Rie, Hayashishita, Yoshiyuki, Shiga, Tohru, Kusumi, Ichiro, Koyama, Tsukasa
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2013
Matèries:
Case Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3804584/
https://ncbi.nlm.nih.gov/pubmed/24204150
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/NDT.S49261
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars